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ABSTRACT Objective: Organ transplantation is one of the clinical scenarios involving ischemia and reperfusion process. Ischemia/reper-
fusion is the pivotal mechanism of organ injury during transplantation. Thus, ischemia/reperfusion (I/R) injury is a biphasic 
phenomenon that can damage the graft by inflammatory responses. The hypothalamic-pituitary-adrenal (HPA) axis is the main 
hormonal system that is activated under the influence of stress. Normal HPA axis activity leading to the release of glucocorticoids 
is essential for homeostasis and survival during stress. Cortisol, a key controller of stress response, is released by the HPA axis. 
The disrupted release of cortisol in response to inflammation has been shown in animal models. Nesfatin-1 is a peptide involved 
in the regulation of homeostasis and has anti-inflammatory as well as anti-ischemic properties. Therefore, we aimed to identify 
the effect of chronic peripheral nesfatin-1 application on the plasma level of cortisol in a rat model of intestinal I/R-based stress. 
Materials and Methods: Two-month-old 28 Wistar Albino male rats that weighed an average of 200–250 g were used and were 
randomly divided into the following four experimental groups (n=7): laparotomy, I/R, nesfatin-1+laparotomy, nesfatin-1+I/R. Blood 
samples were collected in tubes with EDTA. Plasma cortisol levels were analyzed by rat enzyme-linked immunosorbent assay (ELISA) kits.
Results: Statistically significant decrease was found in the plasma level of cortisol in nesfatin-1+I/R group compared with 
I/R group (p=0.026)  
Conclusion: Nesfatin-1 application can inhibit anti-inflammatory responses under the early phase of intestinal I/R and sup-
port immune reactions by reducing plasma cortisol level. This effect of nesfatin-1 may also increase the rejection of grafts 
during transplantation period.  
Keywords: Ischemia/reperfusion injury, nesfatin-1, inflammation, cortisol, hypothalamic-pituitary-adrenal axis, transplantation
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INTRODUCTION
Stress is a physical, chemical, or an emotional factor to which an organism fails to make a satisfactory adaptation 
(1). The hypothalamic-pituitary-adrenal (HPA) axis is the main hormonal system that is activated under the influence 
of stress; acute stress causes a marked increase in glucocorticoid (GC) concentration in blood through the activation 
of this system (2). Multiple systems including immune and cardiovascular systems as well as several hormones such 
as adrenocorticotrophic hormone (ACTH), GCs, and catecholamines are involved in stress response (3). Eventually, 
normal HPA axis activity leading to the rhythmic and episodic release of adrenal GCs is essential for homeostasis and 
survival during stress (4).
Injury caused by oxidative stress occurs in many clinical scenarios involving ischemia and reperfusion such as or-
gan transplantation, hemorrhagic shock, myocardial infarction, and cerebral vascular events (5). Because ischemia 
initiates the injury and reperfusion worsens the ischemic injury owing to inflammatory responses induced by endo-
thelial factors. Subsequently reperfusion triggers cell apoptosis and necrosis, although it is essential for the survival 
of ischemic graft (6, 7). Finally, the primary tissue damage occurs during the reperfusion phase (8). At present, it 
is known that ischemia/reperfusion (I/R) injury is a situation triggering the inflammatory, apoptotic, and immune 
mechanisms, leading to a stress response in the organism.
Cortisol, the most important human GC, is released by the HPA axis in response to inflammation, stress, and other 
types of stimuli (9-11). In animal models, the disrupted release of cortisol in response to inflammation was shown, 
which is of great importance (12).
Recently, Oh-I et al. (13) described a new anorexigenic protein which is derived from nucleobindin 2 (NUCB2) 
and named it NUCB2-encoded satiety and the fat-influencing protein-nesfatin- (14). Nesfatin produces three major 
peptide products such as nesfatin-1 (spanning residues 1–82), nesfatin-2 (residues 85–163), and named it NUCB2-
encoded satiety and the fat-influencing protein as nesfatin (15). Nesfatin-1 is involved in the regulation of homeo-
stasis and has anti-inflammatory, anti-apoptotic, and anti-ischemic properties (13, 16, 17).
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Based on the literature review, in our study, an intestinal I/R-based 
stress model was created to evaluate the effect of chronic periph-
eral nesfatin-1 application on plasma cortisol level in rats. 
MATERIALS and METHODS
Animals and Experimental Conditions
All experimental protocols conducted on animals were consistent 
with the National Institutes of Health Guidelines for the Care and 
Use of Laboratory Animals (NIH Publication No. 85-23) and were 
approved by the Dumlupinar University Ethics Committee of Ani-
mal Care and Usage. In this study, 28 two-month-old Wistar albino 
male rats were used that weighed an average of 200–250 g. They 
were reared under the supervision of a veterinarian and were kept 
in a well-ventilated, noiseless environment, and allowed free access 
to food and water. The rats were housed in a room with controlled 
temperature (23±1°C) and relative humidity (50%±5%), and they 
were kept in transparent plastic cages (42×26×15 cm), each con-
taining three or four rats that were exposed to a 12:12 light–dark 
cycle.
Experimental Design 
The rats were randomly divided into four experimental groups (in 
each group, n=7). The groups were as follows: 1) sham rats un-
derwent laparotomy (L), 2) I/R rats underwent the occlusion of 
the superior mesenteric artery for 30 min followed by 2-h reperfu-
sion (18), 3) nesfatin-1+L rats were treated with intraperitoneal 
nesfatin-1 (i.p.; 0.25 nmol/g) (Phoenix Pharmaceuticals, Catalog 
No: 003-22B) for 10 consecutive days (19) and underwent lapa-
rotomy (N+L), 4) nesfatin-1+I/R rats were treated with i.p. nes-
fatin-1 (0.25 nmol/g) for 10 consecutive days and underwent the 
occlusion of superior mesenteric artery for 30 min followed by 2-h 
reperfusion (N+I/R). 
Blood Samples and Measurements
At the end of the experimental period, all animals were anesthe-
tized with ketamin/xylazine HCl (75 mg/kg/10 mg/kg i.p.). Blood 
samples were collected in tubes with EDTA. After centrifugation, 
plasma samples of each rat were stored at −80°C until ELISA analy-
sis. Plasma cortisol levels (Cusabio Biotech, Cat No CSB-E05112r) 
were analyzed by rat ELISA assay kits. First, we set up a blank well 
without any solution and added 50 μl of standard and sample as well 
as 50 μl antibody to each well, except the blank well. After that plate 
was mixed well for 60 s, it was incubated for 40 min at 37°C. After 
incubation, each well was washed three times with wash buffer (200 
μl) using an autowasher. After the last wash, any remaining wash 
buffer was removed by aspirating. Horseradish peroxidase (HRP)-
conjugate (100 μl) was immediately added to each well, except the 
blank well. The plate was incubated for 30 min at 37°C. Washing 
process was repeated for five times. A total of 90 μl of 3,3′,5,5′-tet-
ramethylbenzidine (TMB) substrate was added to each well and incu-
bated for 20 min at 37°C. Subsequently, 50 μl of stop solution was 
added to each well. Concentration of each sample was calculated 
according to their chemiluminescence data. Chemiluminescence 
data were analyzed by an ELISA microplate reader (das, Digital and 
Analog Systems; Vimercate, MI, Italy). 
Statistical analysis
Statistical analyses were conducted by Statistical Package for Social 
Sciences (SPSS, Inc.; Chicago, IL, USA) 16.0 package program. 
All data were given as mean ± standard deviation (SD). Statistical 
significances among all groups and between the two groups were 
analyzed by Kruskal–Wallis and Mann–Whitney U tests, respec-
tively. Differences were considered to be statistically significant at 
p<0.05.
RESULTS
Plasma Cortisol Levels 
Statistically significant difference was found for the plasma cortisol 
level among the L (6.83±0.14 ng/mL), I/R (7.3±0.083 ng/mL), 
N+L (7.19±0.07 ng/mL), and N+I/R (7.15±0.05 ng/mL) groups 
(p=0.009). The plasma cortisol levels in I/R and N+L groups 
were significantly higher than those in the L group; p=0.004 and 
p=0.038, respectively (Figure 1). A statistically significant decrease 
was found in the plasma cortisol level in N+I/R group compared 
with the I/R group (p=0.026) (Figure 1).
DISCUSSION 
Ischemia/reperfusion is a pathological condition characterized by 
an initial restriction of blood supply to an organ, followed by the 
restoration of perfusion and concomitant reoxygenation. Occlu-
sion of the arterial blood supply results in severely impaired meta-
bolic supply and demand, leading to tissue hypoxia (20, 21). Fur-
thermore, despite the successful reopening of the vascular supply 
system, an ischemic organ may not immediately regain its perfu-
sion (22). Subsequent restoration of blood flow and reoxygenation 
is associated with an exacerbation of tissue injury and a strong 
inflammatory response, which is called as “reperfusion injury” (20, 
21). At present, it is known that ischemia and reperfusion leads 
to the activation of cell death programs, including apoptosis and 
necrosis, and that reperfusion injury is characterized by autoim-
mune responses associated with the activation of innate and adap-
tive immune responses and inflammatory cell trafficking into the 
diseased organ (22-24). Moreover, I/R is the pivotal mechanism 
of the organ  injury  during transplantation and is a multifactorial 
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Figure 1. Plasma cortisol levels in L, I/R, N+L, and N+I/R groups
L: Laparatomy; I/R: Ischemia/reperfusion; N+L: Nesfatin-1+Laparatomy; 
N+I/R: Nesfatin-1+ischemia/reperfusion
*: The significance between L and the other group; p<0.05 (Mann–Whitney 
U test)
#: The significance between I/R and the other group; p<0.05 (Mann–Whitney 
U test)




































process that affects graft function after transplantation (25, 26). The 
reason is that transplantation is always associated with I/R injury as 
well as inflammation and rejection (27). By occurring early in the 
transplant process, I/R initiates a cascade of molecular and cellular 
events; consequently, acute and chronic changes develop, thereby in-
fluencing the structure and function of the organ that may contribute 
to reduced graft survival (28). Additionally, activation of the immune 
system as a result of the disturbances involved in I/R injury contributes 
to tissue and organ damage (5). Based on the literature, I/R injury initi-
ates a chain of events including apoptotic, inflammatory, and immune 
mechanisms that trigger the stress response in the organism. 
The HPA axis (neuroendocrine route, resultant release of GCs, 
namely cortisol) and the sympathetic nervous system (SNS, neural 
route, resultant release of catecholamines, namely noradrenaline 
(NA)/adrenaline and neuropeptides) are the two main pathways 
of the stress response (29). Dysregulation of either of these stress 
systems can lead to the dysregulation of several other physiological 
systems, including the immune system, which leads to a maladap-
tive stress response (29). Because the HPA axis and SNS interact 
with each other in a bidirectional manner and coordinate the re-
sponses of many other physiological systems to a stressor (29-31). 
Although these two systems act together, the HPA axis is the main 
center and the activation of this system provides the animal’s ability 
for adaptation and coping with stress (32).
The end-point of the activation of the HPA axis is the release of 
GCs, i.e., cortisol in humans and corticosterone in rodents, from 
the adrenal cortex into the general circulation (33). The synthesis 
and release of GCs are controlled by ACTH, which is released 
from the anterior pituitary gland. The release of ACTH is regulated 
by corticotropin-releasing factor (CRF) and arginine vasopressin 
(AVP), both of which exert a synergistic action on the release of 
ACTH. In response to acute stress or inflammation, the HPA axis 
is activated, thereby evoking the release of CRF and AVP into the 
hypophysial portal blood; this results in an increased release of 
ACTH and cortisol into the blood (33). Additionally, the degree of 
the activation of HPA axis is closely related to the intensity of stress 
experienced by animals (2). It is known that rats are very sensitive 
to stress so that a mild stressor results in an excessive increase in 
GC levels (34). Because animals respond to a stressor by increasing 
their GC levels, several studies have been focused on measuring 
these hormone levels (35). Up to date, many different techniques 
including sampling from blood and feces have been used to mea-
sure GC concentrations. Consequently, blood GC concentrations 
have been used as an index of stress in several studies (36).
GCs are a class of steroid hormones that have a wide range of bio-
logical activities (37). GCs are secreted in response to inflammation 
and stress, and they potently suppress immunity and inflammatory 
responses (9, 10). Thus, GCs are widely recognized as the regula-
tors of adaptive inflammation, immunity, and stress response in 
the organism (9, 38). Cortisol is the major stress hormone and 
the key controller of the stress response that regulates and sup-
ports various important immunologic, homeostatic, cardiovascular, 
and metabolic functions (11, 37). 
In our study, rats were used to create an intestinal I/R-based ex-
perimental stress model; as an indicator of the stress and inflamma-
tory response, plasma cortisol levels were measured. Statistically 
significant increase in the plasma level of cortisol was observed 
in the I/R group compared with L group. We suppose that this 
increase in cortisol level in the I/R group was a result of stress 
and inflammatory response, consistent with the findings in the lit-
erature. Although it may be advantageous to measure the plasma 
corticosterone level instead of cortisol level in rats, we measured 
the plasma cortisol level, which was a limitation of our study. 
Nesfatin-1 is an 82-amino acid peptide that is involved in food 
restriction and in the regulation of homeostasis (13, 15, 39). Nes-
fatin-1 is localized in neurons of the hypothalamus and brain stem 
and is colocalized with stress-related substances such as CRF, oxy-
tocin, proopiomelanocortin, NA, and 5-hydroxytryptamine (5-HT) 
(40). It is suggested that there is a link between nesfatin-1 and 
stress responses because the central nesfatin-1 system is stimulated 
by stress and activates CRH, NA, and 5-HT neurons as well as 
the HPA axis, thereby evoking both central and peripheral stress 
responses (40, 41). According to the literature, nesfatin-1 has 
homeostatic, anti-ischemic, anti-inflammatory, and anti-apoptotic 
properties (13, 16, 17). Thus, we aimed to investigate the effect of 
nesfatin-1 on the plasma level of cortisol in a rat model of intestinal 
I/R-based stress.
In a study by Merali et al. (42), it was reported that the intra-
cerebroventricular (ICV) administration of nesfatin-1 potentiates 
stressor-induced increases in plasma ACTH and corticosterone 
levels in rats. Angelone et al. (16) suggested that nesfatin-1 pro-
tects the heart against I/R injury by reducing infarct size and re-
leasing lactate dehydrogenase as well as by post-ischemic con-
tracture. Özsavci et al. (17) reported that  nesfatin-1 exerted a 
neuroprotective effect in subarachnoid hemorrhage-induced in-
jury in rats by inhibiting neutrophil infiltration and the subsequent 
release of inflammatory mediators. 
It has been shown that nesfatin-1 has anti-inflammatory effect un-
der different conditions (17, 43). To our knowledge, we could not 
observe any reports about the effect of nesfatin-1 in laparotomy. In 
our study, as expected, a significant increase in the plasma cortisol 
level was observed in the N+L group compared with the L group by 
chronic i.p. nesfatin-1 application. In contrast, a significant decrease 
was observed in the plasma level of cortisol in the N+I/R group 
compared with the I/R group. Based on our findings, we can say 
that the release of cortisol was suppressed by nesfatin-1 applica-
tion, particularly under stress conditions such as I/R. Interestingly, 
this finding indicated the dual effect of nesfatin-1, which means that 
nesfatin-1 behaves differently in different conditions. We suggest 
that there is a central inhibitor effect of nesfatin-1 on the release of 
cortisol, although we cannot explain the exact mechanism for the 
suppression of cortisol by nesfatin-1 in the N+I/R group. Also, we 
suppose that chronic peripheral nesfatin-1 application can inhibit 
anti-inflammatory responses under the early phase of intestinal I/R 
and support immune reactions by reducing plasma cortisol level. Be-
cause of the fact that I/R is an important part of organ transplanta-
tion, we hypothesize that this effect of nesfatin-1 also increases the 
rejection of grafts during transplantation period. 
Finally, better understanding of the mechanisms involved in I/R 
injury provides a new perspective to the development of the 
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therapeutic strategies, which will improve the outcomes of trans-
plantation. Here, we emphasized that nesfatin-1 may increase 
the rejection of grafts during transplantation period by inhibiting 
anti-inflammatory responses through the reduction of cortisol lev-
els, although it is gaining attention as an anti-inflammatory agent. 
However, further experimental studies are essential to clarify the 
effect of nesfatin-1 on the immune system in different physiological 
and pathophysiological conditions.
CONCLUSION
Chronic peripheral nesfatin-1 application can inhibit anti-inflam-
matory responses under the early phase of intestinal I/R and sup-
port immune reactions by reducing plasma cortisol levels. This ef-
fect of nesfatin-1 may also increase the rejection of grafts during 
the transplantation period.   
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